Regeneron Pharmaceuticals (REGN) Competitors

Regeneron Pharmaceuticals currently has a consensus target price of $800.36, suggesting a potential downside of 0.90%. Gilead Sciences has a consensus target price of $158.04, suggesting a potential upside of 8.50%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.3%. Regeneron Pharmaceuticals pays out 9.3% of its earnings in the form of a dividend. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Gilead Sciences' net margin of -10.64%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Gilead Sciences' return on equity.

In the previous week, Regeneron Pharmaceuticals had 8 more articles in the media than Gilead Sciences. MarketBeat recorded 47 mentions for Regeneron Pharmaceuticals and 39 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.91 beat Regeneron Pharmaceuticals' score of 0.47 indicating that Gilead Sciences is being referred to more favorably in the news media.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Regeneron Pharmaceuticals has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Moderna has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

Regeneron Pharmaceuticals presently has a consensus price target of $800.36, suggesting a potential downside of 0.90%. Moderna has a consensus price target of $76.72, suggesting a potential downside of 43.42%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Moderna.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Moderna's net margin of -141.43%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Moderna's return on equity.

In the previous week, Regeneron Pharmaceuticals had 6 more articles in the media than Moderna. MarketBeat recorded 47 mentions for Regeneron Pharmaceuticals and 41 mentions for Moderna. Regeneron Pharmaceuticals' average media sentiment score of 0.47 beat Moderna's score of 0.41 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Regeneron Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Regeneron Pharmaceuticals presently has a consensus target price of $800.36, suggesting a potential downside of 0.90%. Intellia Therapeutics has a consensus target price of $20.98, suggesting a potential upside of 71.81%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than Regeneron Pharmaceuticals.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Regeneron Pharmaceuticals has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market.

In the previous week, Regeneron Pharmaceuticals had 25 more articles in the media than Intellia Therapeutics. MarketBeat recorded 47 mentions for Regeneron Pharmaceuticals and 22 mentions for Intellia Therapeutics. Regeneron Pharmaceuticals' average media sentiment score of 0.47 beat Intellia Therapeutics' score of 0.47 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Intellia Therapeutics' net margin of -672.16%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Intellia Therapeutics' return on equity.

Regeneron Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Vir Biotechnology presently has a consensus price target of $21.57, indicating a potential upside of 99.55%. Regeneron Pharmaceuticals has a consensus price target of $800.36, indicating a potential downside of 0.90%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, equities analysts clearly believe Vir Biotechnology is more favorable than Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Vir Biotechnology has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market.

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Regeneron Pharmaceuticals had 43 more articles in the media than Vir Biotechnology. MarketBeat recorded 47 mentions for Regeneron Pharmaceuticals and 4 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.33 beat Regeneron Pharmaceuticals' score of 0.47 indicating that Vir Biotechnology is being referred to more favorably in the media.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Vir Biotechnology's net margin of -638.88%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Vir Biotechnology's return on equity.